HIRA to curb NHI payment on Zyprexa

Published: 2002-10-02 06:58:00

Updated: 2002-10-02 06:58:00

The Health Insurance Review Agency (HIRA) decided to control the NHI payment on Zyprexa, a major tranquilizer (E. Lilly) by classifying it as the 2nd choice of drugs, on the ground that it had no any significant difference in its therapeutic effect with other preparations except a minor side effect.

In the parliamentary inspection of the government administration by the National Assembly, th...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.